ClinicalTrials.gg
CompletedNCT03813199Updated Feb 15, 2023Results posted

Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

A Phase 2 interventional study of ABX464 50mg and Matching Placebo in Rheumatoid Arthritis, sponsored by Abivax S.A.. Completed at 24 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 357 studies in Arthritis, Rheumatoid with a site in France — 42 open to participants now, 62 under way, 6 of them phase 3. Arthritis, Rheumatoid · France.

Enrollment
164th of 222
60 · median 167
Started
2019
with 18 others
Phase 2
33 of 357
4 open now
Registered
230th of 357
by date

Among the 357 studies in Arthritis, Rheumatoid with a site in France, this one is the 164th largest by enrollment of the 222 interventional ones that give a count, is one of 19 that started in 2019, is one of 33 in phase 2, and was the 230th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

42 of the 357 studies in Arthritis, Rheumatoid with a site in France are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 357 studies in Arthritis, Rheumatoid with a site in France, or all of them as a file.
02

Study summary

This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who had an inadequate response to MTX or/and to one or more anti- tumor necrosis factor alpha (TNFα) therapies.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter study. The study will consist of 3 phases: a screening phase, a treatment phase, and a follow-up phase.

Approximately 60 participants with active Rheumatoid Arthritis will be randomly assigned to receive placebo, 50mg ABX464 or 100mg ABX464 during the treatment phase.

The maximum period of active treatment will be 12 weeks. The maximum duration of study participation will be 17 weeks.

Participant safety will be monitored throughout the study. In addition, several experimental and clinical endpoints will be assessed to obtain information on preliminary efficacy.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a confirmed and documented diagnosis of adult-onset rheumatoid arthritis, for at least 12 weeks, according to the revised 2010 American College of Rheumatology- European League Against Rheumatism (ACR-EULAR) classification criteria, including at least one positive criteria among the following: Rheumatoid Factor (RF), Anti-Citrullinated Peptide Antibody (ACPA) or bone erosion;
  • Swollen joint count (SJC) of ≥ 4 (28-joint count) and tender joint count (TJC) ≥4 (28-joint count) at screening;
  • Patient with a moderate to severe disease activity score Disease Activity Score (28 joints) C-Reactive Protein [DAS28 CRP] ≥ 3.2 and C-reactive Protein (CRP) ≥ 5 mg/L (≥ 4.76 nmol)/L) at screening;
  • Patient who had an inadequate response (IR), or failed either methotrexate (MTX) or/and anti- Tumor Necrosis Factor alpha (TNFα) therapy (both administered for at least 12 weeks before IR) or were intolerant to anti- TNFα therapy.

Exclusion criteria

Exclusion Criteria:

  • Patient with a known positive anti-double stranded deoxyribonucleic acid (DNA [anti-dsDNA]) and confirmed diagnosis of systemic lupus erythematosus (SLE);
  • Patient with known active infections at screening such as CytoMegaloVirus (CMV), herpes virus and/or recent infectious hospitalization;
  • Acute, chronic or history of pulmonary, cardiovascular, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable Central Nervous System (CNS) pathology such as seizure disorder, angina or cardiac arrhythmias, active or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history;
  • Acute, chronic or history of immunodeficiency or other disease;
  • Patient previously treated with any non-anti-TNF biological Disease-Modifying AntiRheumatic Drugs (bDMARDs), and targeted DMARDs (tDMARDS) prior to baseline.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ABX464 50mg + methotrexate

    Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks + methotrexate

    Drug: ABX464 50mg · Drug: Matching Placebo · Drug: Methotrexate

  • Experimental
    ABX464 100mg + methotrexate

    Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks + methotrexate

    Drug: ABX464 100mg · Drug: Methotrexate

  • Placebo comparator
    Placebo + methotrexate

    Participants will receive two capsules of matching placebo once daily for 12 weeks + methotrexate

    Drug: Matching Placebo · Drug: Methotrexate

Interventions

  • ABX464 is a new anti-inflammatory drug

    Also known as: obefazimod 50mg

  • DrugMatching Placebo

    placebo matching with ABX464

    Also known as: Placebo

  • ABX464 is a new anti-inflammatory drug

    Also known as: obefazimod 100mg

  • MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study

    Also known as: MTX

06

What researchers measure

Primary outcomes

  1. Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo

    TEAE definition is undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment

    Time frame: through study completion, an average of 15 weeks

Secondary outcomes

  1. Number of Patients Achieving ACR20 Response

    The categorical American College of Rheumatology 20% (ACR20) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% improvement in the ACR response.

    Time frame: at Week 12

  2. Number of Patients Achieving ACR20/50/70 Response

    Number of patients who achieved at least 20%, 50% or 70% improvement in the American College of Rheumatology (ACR) response.

    Time frame: Week 12

  3. Change From Baseline in C-reactive Protein (CRP)

    Change from baseline in C-reactive protein (CRP) at Week 12

    Time frame: Week 12

  4. Number of Patients Achieving DAS28-CRP Response

    Number of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) \[DAS28-CRP\] response will be measured as moderate/good European League Against Rheumatism (EULAR) response

    Time frame: Week 12

  5. Change From Baseline in Disease Activity Scores (DAS-CRP) (28 Joints) [DAS28]

    The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (CRP ), and patient's global assessment of disease activity (PtGA). DAS28-CRP = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.36 Ln \[CRP(mg/L)+1\] + 0.014 PtGA(VAS100mm) + 0.96 Score scale range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

    Time frame: Week 12

  6. Change From Baseline in Erythrocyte Sedimentation Rate (ESR)

    Change from baseline in erythrocyte sedimentation rate (ESR) at Week 12

    Time frame: Week 12

  7. Number of Patients Achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) [DAS28-ESR] Remission

    Number of patients achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) \[DAS28-ESR\]remission, which is defined as DAS2-ESR \< 2.6

    Time frame: Week 12

  8. Change From Baseline in Disease Activtiy Score (DAS)28-Erythrocyte Sedimentation Rate (ESR)

    The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (ESR), and patient's global assessment of disease activity (PtGA). DAS28-ESR = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.70 Ln \[ESR(mm/h)\] + 0.014 PtGA(VAS100mm) Score scale range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. change from baseline at weeks 12: the bigger negative score shows a bigger improvment

    Time frame: 12 weeks

  9. Change From Baseline in Simplified Disease Activity Index Score (SDAI)

    SDAI is a validated index of rheumatoid arthritis disease activity. The SDAI calculation is based on 28 tender and swollen joint counts, C-Reactive Protein (CRP), patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA). SDAI score= tender28 + swollen28 + CRP + (PtGA/10) + (PrGA/10). A moderate activity is defined by a SDAI score \>11 to 26 included. A high activity is defined by a SDAI score \>26. Change from Baseline: the higher negative number shows a bigger improvment

    Time frame: Week 12

  10. Change From Baseline in Clinical Disease Activity Index Score (CDAI)

    CDAI is a validated index of rheumatoid arthritis disease activity. The CDAI calculation is based on 28 tender and swollen joint counts, patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA). CDAI score= tender28 + swollen28 + (PtGA/10) + (PrGA/10). A moderate activity is defined by a CDAI score \>10 to 22 included. A high activity is defined by a CDAI score \>22. Change from Baseline: the higher negative number shows a bigger improvment

    Time frame: Week 12

  11. Number of Patients Achieving Low Disease Activity (LDA)

    Number of patients achieving a Low Disease Activity (LDA) which is defined as DAS28-ESR \<=3.2

    Time frame: Week 12

  12. Number of Patients Achieving Simplified Disease Activity Score (SDAI) Remission

    Number of patients achieving Simplified Disease Activity Score (SDAI) remission, which is considered achieved if the SDAI score ≤ 3.3

    Time frame: Week 12

  13. Number of Patients Achieving Clinical Disease Activity (CDAI) Remission

    Number of patients achieving Clinical Disease Activity (CDAI) remission, which is considered achieved if the CDAI score ≤ 2.8

    Time frame: Week 12

  14. Number of Patients Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission

    The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1

    Time frame: Week 12

  15. Change From Baseline in Tender/Painful Joint Count (TJC28)

    Change from Baseline in Tender/painful joint count based on 28-joint assessment (TJC28) at Week 12 TJC28 score range from 0 to 28 Change from Baseline: the higher the negative number is, the better improvment is

    Time frame: 12 weeks

  16. Change From Baseline in Swollen Joint Count (SJC)

    Change from Baseline in Swollen joint count based on 28-joint assessment (SJC28) at Week 12 SJC28 score range from 0 to 28 Change from Baseline: the higher the negative number is, the better improvment is

    Time frame: 12 weeks

  17. Change From Baseline in Pain Visual Analog Scale

    Change from Baseline in Pain Visual Analog Scale (Pain-VAS) at week 12 The VAS range from 0 to 10 cm (the higher, the more painful) A bigger negative change from baseline shows a bigger improvment

    Time frame: 12 weeks

  18. Change From Baseline in Patient Global Assessment of Disease (PtGA)

    Change from Baseline in Patient Global Assessment of Disease (PtGA) . This is a patient's self assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity The change from baseline: a bigger negative number shows a bigger improvment

    Time frame: 12 weeks

  19. Change From Baseline in Investigator Global Assessment of Disease (PrGA)

    Change from Baseline in Investigator global assessment of disease (PrGA): investigator's assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity The change from baseline: the higher negative number shows a better improvement

    Time frame: 12 weeks

  20. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

    Change from Baseline in Health Assessment questionnaire disability index (HAQ-DI) at Week 12 There are 8 sections in this questionnaire: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section, i.e. if one question is scored 1 and another 2, then the score for the section is 2. In addition, if an aide or device is used or if help is required from another individual, then the minimum score for that section is 2. The 8 scores of the 8 sections are summed and divided by the number of section answered. This gives a score range from 0 to 3 (the bigger the worst activity). The change from Baseline: the bigger negative number shows a bigger improvment

    Time frame: 12 weeks

07

Results

Posted Apr 7, 2022

Participant flow

Participant flow — Overall Study
MilestoneABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Started211920
Completed18619
Not completed3131

Outcome measures

PrimaryNumber of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo

TEAE definition is undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment

Time frame:
through study completion, an average of 15 weeks
Reported as:
Count of participants · Participants
Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo181814
SecondaryNumber of Patients Achieving ACR20 Response

The categorical American College of Rheumatology 20% (ACR20) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% improvement in the ACR response.

Time frame:
at Week 12
Reported as:
Count of participants · Participants
Number of Patients Achieving ACR20 Response
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Number of Patients Achieving ACR20 Response934
SecondaryNumber of Patients Achieving ACR20/50/70 Response

Number of patients who achieved at least 20%, 50% or 70% improvement in the American College of Rheumatology (ACR) response.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Achieving ACR20/50/70 Response
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
ACR20 response934
ACR50 response521
ACR70 response411
SecondaryChange From Baseline in C-reactive Protein (CRP)

Change from baseline in C-reactive protein (CRP) at Week 12

Time frame:
Week 12
Reported as:
Mean · mg/L
Change From Baseline in C-reactive Protein (CRP)
mg/LABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in C-reactive Protein (CRP)-4.31 ± 28.830.62 ± 4.89-0.65 ± 18.74
SecondaryNumber of Patients Achieving DAS28-CRP Response

Number of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) \[DAS28-CRP\] response will be measured as moderate/good European League Against Rheumatism (EULAR) response

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Achieving DAS28-CRP Response
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Number of Patients Achieving DAS28-CRP Response1468
SecondaryChange From Baseline in Disease Activity Scores (DAS-CRP) (28 Joints) [DAS28]

The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (CRP ), and patient's global assessment of disease activity (PtGA). DAS28-CRP = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.36 Ln \[CRP(mg/L)+1\] + 0.014 PtGA(VAS100mm) + 0.96 Score scale range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Disease Activity Scores (DAS-CRP) (28 Joints) [DAS28]
score on a scaleABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Disease Activity Scores (DAS-CRP) (28 Joints) [DAS28]-1.41 ± 1.45-0.72 ± 1.13-0.60 ± 0.98
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate (ESR)

Change from baseline in erythrocyte sedimentation rate (ESR) at Week 12

Time frame:
Week 12
Reported as:
Mean · mm/h
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
mm/hABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)-2.6 ± 19.3-0.3 ± 6.8-2.7 ± 16.6
SecondaryNumber of Patients Achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) [DAS28-ESR] Remission

Number of patients achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) \[DAS28-ESR\]remission, which is defined as DAS2-ESR \< 2.6

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) [DAS28-ESR] Remission
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Number of Patients Achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) [DAS28-ESR] Remission200
SecondaryChange From Baseline in Disease Activtiy Score (DAS)28-Erythrocyte Sedimentation Rate (ESR)

The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (ESR), and patient's global assessment of disease activity (PtGA). DAS28-ESR = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.70 Ln \[ESR(mm/h)\] + 0.014 PtGA(VAS100mm) Score scale range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. change from baseline at weeks 12: the bigger negative score shows a bigger improvment

Time frame:
12 weeks
Reported as:
Mean · mm/h
Change From Baseline in Disease Activtiy Score (DAS)28-Erythrocyte Sedimentation Rate (ESR)
mm/hABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Disease Activtiy Score (DAS)28-Erythrocyte Sedimentation Rate (ESR)-1.43 ± 1.39-0.74 ± 1.11-0.59 ± 1.00
SecondaryChange From Baseline in Simplified Disease Activity Index Score (SDAI)

SDAI is a validated index of rheumatoid arthritis disease activity. The SDAI calculation is based on 28 tender and swollen joint counts, C-Reactive Protein (CRP), patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA). SDAI score= tender28 + swollen28 + CRP + (PtGA/10) + (PrGA/10). A moderate activity is defined by a SDAI score \>11 to 26 included. A high activity is defined by a SDAI score \>26. Change from Baseline: the higher negative number shows a bigger improvment

Time frame:
Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Simplified Disease Activity Index Score (SDAI)
score on a scaleABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Simplified Disease Activity Index Score (SDAI)-20.21 ± 33.27-9.37 ± 14.44-7.58 ± 22.69
SecondaryChange From Baseline in Clinical Disease Activity Index Score (CDAI)

CDAI is a validated index of rheumatoid arthritis disease activity. The CDAI calculation is based on 28 tender and swollen joint counts, patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA). CDAI score= tender28 + swollen28 + (PtGA/10) + (PrGA/10). A moderate activity is defined by a CDAI score \>10 to 22 included. A high activity is defined by a CDAI score \>22. Change from Baseline: the higher negative number shows a bigger improvment

Time frame:
Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Disease Activity Index Score (CDAI)
score on a scaleABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Clinical Disease Activity Index Score (CDAI)-15.89 ± 13.29-9.99 ± 15.85-6.93 ± 10.13
SecondaryNumber of Patients Achieving Low Disease Activity (LDA)

Number of patients achieving a Low Disease Activity (LDA) which is defined as DAS28-ESR \<=3.2

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Achieving Low Disease Activity (LDA)
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Number of Patients Achieving Low Disease Activity (LDA)422
SecondaryNumber of Patients Achieving Simplified Disease Activity Score (SDAI) Remission

Number of patients achieving Simplified Disease Activity Score (SDAI) remission, which is considered achieved if the SDAI score ≤ 3.3

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Achieving Simplified Disease Activity Score (SDAI) Remission
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Number of Patients Achieving Simplified Disease Activity Score (SDAI) Remission100
SecondaryNumber of Patients Achieving Clinical Disease Activity (CDAI) Remission

Number of patients achieving Clinical Disease Activity (CDAI) remission, which is considered achieved if the CDAI score ≤ 2.8

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Achieving Clinical Disease Activity (CDAI) Remission
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Number of Patients Achieving Clinical Disease Activity (CDAI) Remission300
SecondaryNumber of Patients Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission

The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission
ParticipantsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Number of Patients Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission100
SecondaryChange From Baseline in Tender/Painful Joint Count (TJC28)

Change from Baseline in Tender/painful joint count based on 28-joint assessment (TJC28) at Week 12 TJC28 score range from 0 to 28 Change from Baseline: the higher the negative number is, the better improvment is

Time frame:
12 weeks
Reported as:
Mean · joints
Change From Baseline in Tender/Painful Joint Count (TJC28)
jointsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Tender/Painful Joint Count (TJC28)-6.8 ± 6.4-4.1 ± 6.6-2.9 ± 3.8
SecondaryChange From Baseline in Swollen Joint Count (SJC)

Change from Baseline in Swollen joint count based on 28-joint assessment (SJC28) at Week 12 SJC28 score range from 0 to 28 Change from Baseline: the higher the negative number is, the better improvment is

Time frame:
12 weeks
Reported as:
Mean · joints
Change From Baseline in Swollen Joint Count (SJC)
jointsABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Swollen Joint Count (SJC)-4.4 ± 4.2-3.2 ± 5.3-2.1 ± 4.2
SecondaryChange From Baseline in Pain Visual Analog Scale

Change from Baseline in Pain Visual Analog Scale (Pain-VAS) at week 12 The VAS range from 0 to 10 cm (the higher, the more painful) A bigger negative change from baseline shows a bigger improvment

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Pain Visual Analog Scale
units on a scaleABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Pain Visual Analog Scale-2.63 ± 2.43-0.89 ± 1.97-0.78 ± 2.36
SecondaryChange From Baseline in Patient Global Assessment of Disease (PtGA)

Change from Baseline in Patient Global Assessment of Disease (PtGA) . This is a patient's self assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity The change from baseline: a bigger negative number shows a bigger improvment

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Patient Global Assessment of Disease (PtGA)
units on a scaleABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Patient Global Assessment of Disease (PtGA)-1.44 ± 1.92-0.89 ± 1.93-0.36 ± 2.16
SecondaryChange From Baseline in Investigator Global Assessment of Disease (PrGA)

Change from Baseline in Investigator global assessment of disease (PrGA): investigator's assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity The change from baseline: the higher negative number shows a better improvement

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Investigator Global Assessment of Disease (PrGA)
units on a scaleABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Investigator Global Assessment of Disease (PrGA)-3.26 ± 2.7-1.89 ± 2.95-1.63 ± 2.38
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

Change from Baseline in Health Assessment questionnaire disability index (HAQ-DI) at Week 12 There are 8 sections in this questionnaire: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section, i.e. if one question is scored 1 and another 2, then the score for the section is 2. In addition, if an aide or device is used or if help is required from another individual, then the minimum score for that section is 2. The 8 scores of the 8 sections are summed and divided by the number of section answered. This gives a score range from 0 to 3 (the bigger the worst activity). The change from Baseline: the bigger negative number shows a bigger improvment

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
units on a scaleABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)-0.4345 ± 0.6182-0.1053 ± 0.3443-0.1813 ± 0.4824

Adverse events

Collected over 15 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABX464 50mg + Methotrexate0/21 (0%)0/21 (0%)15/21 (71.4%)
ABX464 100mg + Methotrexate0/19 (0%)1/19 (5.3%)17/19 (89.5%)
Placebo + Methotrexate0/20 (0%)1/20 (5%)5/20 (25%)
Most frequent serious events
Most frequent serious events
EventABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
Atrial fibrillationCardiac disorders0/211/190/20
Covid-19Infections and infestations0/210/191/20
Most frequent other events
Most frequent other events
EventABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + Methotrexate
HeadacheNervous system disorders8/2110/194/20
nauseaGastrointestinal disorders3/219/190/20
DiarrhoeaGastrointestinal disorders4/217/191/20
Abdominal pain upperGastrointestinal disorders5/214/191/20
DyspepsiaGastrointestinal disorders1/213/190/20
VomitingGastrointestinal disorders2/213/190/20
ArthralgiaMusculoskeletal and connective tissue disorders0/212/191/20
abdominal painGastrointestinal disorders2/211/190/20
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/211/191/20
CoughRespiratory, thoracic and mediastinal disorders2/211/190/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)ABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + MethotrexateTotal
Mean57.9 ± 11.454.4 ± 10.658.6 ± 11.057.0 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)ABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + MethotrexateTotal
Female15111137
Male68923
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ABX464 50mg + MethotrexateABX464 100mg + MethotrexatePlacebo + MethotrexateTotal
Count of participants———0
08

Study locations

24 sites
  • Cliniques Universitaires Saint-Luc
    Bruxelles, Belgium
  • UZ Gent
    Gent, Belgium
  • UZ Leuven
    Leuven, Belgium
  • ZNA Jan Palfijn
    Merksem, Belgium
  • Fakultni Tomayerova nemocnice
    Praha, Czechia
  • Revmatologicky ustav
    Praha, Czechia
  • CHU de Brest - Hôpital Cavale Blanche
    Brest, France
  • CHD Vendée
    La Roche-sur-Yon, France
  • CHU de Montpellier - Lapeyronie
    Montpellier, France
  • GHR Mulhouse Sud-Alsace
    Mulhouse, France
  • CHU de Nice - Hôpital Pasteur
    Nice, France
  • CHR d'Orléans
    Orléans, France
  • APHP - Hôpital Salpétrière
    Paris, France
  • CHU de Tours - Hôpital Trousseau
    Tours, France
  • Complex Medical Centre - Déli Klinika
    Budapest, Hungary
  • CRU Hungary Ltd.
    Miskolc, Hungary
  • CMed Rehabilitációs és Diagnosztikai Központ
    Székesfehérvár, Hungary
  • ClinicMed Daniluk, Nowak Sp. J.
    Białystok, Poland
  • Pratia MCM
    Kraków, Poland
  • Zespół Poradni Specjalistycznych REUMED
    Lublin, Poland
  • NZOZ Lecznica MAK-MED S.C.
    Nadarzyn, Poland
  • Medyczne Centrum Hetmańska
    Poznań, Poland
  • National Institute of Geriatrics
    Warszawa, Poland
  • RHEUMA MEDICUS Zakład Opieki Zdrowotnej
    Warszawa, Poland
09

References and documents

Publications

  • Daien C, Krogulec M, Gineste P, Steens JM, Desroys du Roure L, Biguenet S, Scherrer D, Santo J, Ehrlich H, Durez P. Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFalpha therapy: a placebo-controlled phase II study. Ann Rheum Dis. 2022 Jul 12;81(8):1076-1084. doi: 10.1136/annrheumdis-2022-222228. PubMed 35641124 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Apr 2021, 21 months.

Results were first posted in Apr 2022, 11 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2019
First posted
Jan 23, 2019
StartActual
Jul 4, 2019
Primary completionActual
Apr 27, 2021
CompletionActual
Apr 27, 2021
Results first posted
Apr 7, 2022
Last update
Feb 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03813199
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Jan 23, 2019
Start date
Jul 4, 2019
Primary completion
Apr 27, 2021
Completion
Apr 27, 2021
Results posted
Apr 7, 2022
Last update
Feb 15, 2023

Study contacts

Paul GINESTE, PharmD
study director · Abivax S.A.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion